32.24
Schlusskurs vom Vortag:
$31.60
Offen:
$32
24-Stunden-Volumen:
37,973
Relative Volume:
0.05
Marktkapitalisierung:
$2.06B
Einnahmen:
$681.88M
Nettoeinkommen (Verlust:
$122.63M
KGV:
15.28
EPS:
2.11
Netto-Cashflow:
$220.18M
1W Leistung:
+0.21%
1M Leistung:
-6.87%
6M Leistung:
-6.63%
1J Leistung:
+5.62%
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Firmenname
Harmony Biosciences Holdings Inc
Sektor
Branche
Telefon
(484) 539-9800
Adresse
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Vergleichen Sie HRMY mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
HRMY
Harmony Biosciences Holdings Inc
|
32.21 | 2.06B | 681.88M | 122.63M | 220.18M | 2.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
446.49 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
522.51 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
321.96 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
558.87 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
241.11 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
2024-12-17 | Eingeleitet | H.C. Wainwright | Buy |
2024-10-10 | Fortgesetzt | Raymond James | Outperform |
2024-09-10 | Eingeleitet | UBS | Buy |
2024-06-21 | Eingeleitet | Citigroup | Buy |
2024-01-02 | Herabstufung | BofA Securities | Neutral → Underperform |
2023-09-25 | Herabstufung | Goldman | Neutral → Sell |
2023-09-07 | Eingeleitet | Berenberg | Buy |
2023-04-20 | Eingeleitet | BofA Securities | Neutral |
2022-10-14 | Hochstufung | Janney | Neutral → Buy |
2022-10-14 | Hochstufung | Jefferies | Hold → Buy |
2022-08-03 | Herabstufung | Jefferies | Buy → Hold |
2022-07-13 | Herabstufung | Goldman | Buy → Neutral |
2022-07-07 | Eingeleitet | Mizuho | Buy |
2022-04-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
2021-11-04 | Eingeleitet | Raymond James | Outperform |
2021-09-23 | Eingeleitet | Needham | Buy |
2021-03-29 | Hochstufung | Goldman | Neutral → Buy |
2020-09-14 | Eingeleitet | Goldman | Neutral |
2020-09-14 | Eingeleitet | Jefferies | Buy |
2020-09-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten
Lupin Concedes To Harmony On Generic Wakix With 2030 Launch Agreement - insights.citeline.com
Harmony Biosciences Presents Promising Preclinical Data for Novel Narcolepsy Treatment - MyChesCo
Rhumbline Advisers Increases Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
(HRMY) Investment Analysis - news.stocktradersdaily.com
Equities Analysts Set Expectations for HRMY FY2026 Earnings - Defense World
Harmony Biosciences Presents Preclinical Data Demonstrating Sign - GuruFocus
Harmony Biosciences to begin human trials of narcolepsy drug in 2025 By Investing.com - Investing.com South Africa
Harmony Biosciences to begin human trials of narcolepsy drug in 2025 - Investing.com Canada
HRMY: Harmony Biosciences Shows Promising Preclinical Data for BP1.15205 | HRMY Stock News - GuruFocus
Harmony Biosciences (HRMY) Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 - StreetInsider
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025 - Business Wire
Harmony Biosciences Holdings, Inc. (HRMY): A Bull Case Theory - MSN
Harmony Biosciences Reaches Settlement with Lupin Over WAKIX® Patent Litigation - MSN
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by California State Teachers Retirement System - Defense World
Transcript : Harmony Biosciences Holdings, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 03 - MarketScreener
Harmony Biosciences settles patent litigation with Lupin By Investing.com - Investing.com South Africa
Harmony Biosciences, Lupin reach agreement on Wakix generic launch - MSN
Harmony Biosciences: If It Ain't Broke (NASDAQ:HRMY) - Seeking Alpha
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation - BioSpace
Harmony Biosciences (HRMY) Settles Patent Dispute with Lupin | HRMY Stock News - GuruFocus
Harmony Biosciences settles patent litigation with Lupin - Investing.com Australia
Harmony Biosciences Strengthens Patent Position With Favorable Settlement In ANDA Litigation - MarketScreener
Harmony Biosciences Strengthens Patent Position With Favorable S - GuruFocus
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation | HRMY Stock News - GuruFocus
Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference | HRMY Stock News - GuruFocus
Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference - Yahoo Finance
Top 5 US Stocks To Buy In June 2025 - Investing.com
Harmony Biosciences (NASDAQ:HRMY) Now Covered by Analysts at Oppenheimer - Defense World
Where Harmony Biosciences Hldgs Stands With Analysts - Benzinga
Oppenheimer Sets $61 Price Target for Harmony Biosciences (HRMY) | HRMY Stock News - GuruFocus
(HRMY) On The My Stocks Page - news.stocktradersdaily.com
Oppenheimer assumes Outperform rating on Harmony Biosciences stock By Investing.com - Investing.com Nigeria
Oppenheimer assumes Outperform rating on Harmony Biosciences stock - Investing.com
Harmony Biosciences (HRMY) Receives Outperform Rating from Oppen - GuruFocus
Oppenheimer Assumes Harmony Biosciences Holdings Inc. (HRMY) at Outperform - StreetInsider
Oppenheimer Sets $61 Price Target for Harmony Biosciences (HRMY) - GuruFocus
Nuveen Asset Management LLC Buys 8,193 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Bank of America Corp DE Decreases Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Ameriprise Financial Inc. Purchases 18,730 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of “Buy” by Analysts - Defense World
When (HRMY) Moves Investors should Listen - news.stocktradersdaily.com
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Bought by Deutsche Bank AG - Defense World
A Piece Of The Puzzle Missing From Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) 26% Share Price Climb - simplywall.st
BNP Paribas Financial Markets Invests $2.03 Million in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Harmony Biosciences (NASDAQ:HRMY) Price Target Raised to $48.00 - Defense World
The Manufacturers Life Insurance Company Acquires 2,144 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock Position Increased by Northern Trust Corp - Defense World
Comerica Bank Acquires 2,919 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Harmony Biosciences (NASDAQ:HRMY) Upgraded at Cantor Fitzgerald - Defense World
Harmony Biosciences (HRMY): Mizuho Raises Price Target to $48 | - GuruFocus
Finanzdaten der Harmony Biosciences Holdings Inc-Aktie (HRMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):